Do analysts rate NNVC or ENVB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NanoViricides 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, NNVC or ENVB?

NanoViricides is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NanoViricides N/A N/A -$8.29M -$0.43 N/A Enveric Biosciences N/A N/A -$8.77M -$23.54 N/A

Is NNVC or ENVB more profitable?

NanoViricides' return on equity of -87.90% beat Enveric Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets NanoViricides N/A -87.90% -78.69% Enveric Biosciences N/A -220.97% -177.47%

Do analysts prefer ENVB or SCYX?

SCYNEXIS has a consensus target price of $24.00, suggesting a potential upside of 390.80%. Given SCYNEXIS's stronger consensus rating and higher probable upside, analysts clearly believe SCYNEXIS is more favorable than Enveric Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SCYNEXIS 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to ENVB or SCYX?

In the previous week, Enveric Biosciences and Enveric Biosciences both had 1 articles in the media. Enveric Biosciences' average media sentiment score of 0.96 beat SCYNEXIS's score of 0.93 indicating that Enveric Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enveric Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SCYNEXIS 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend APLM or ENVB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, APLM or ENVB?

Enveric Biosciences has lower revenue, but higher earnings than Apollomics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 3.61 -$10.94M N/A N/A Enveric Biosciences N/A N/A -$8.77M -$23.54 N/A

Is APLM or ENVB more profitable?

Apollomics' return on equity of 0.00% beat Enveric Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A Enveric Biosciences N/A -220.97% -177.47%

Do analysts rate CPHI or ENVB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor CPHI or ENVB?

In the previous week, China Pharma and China Pharma both had 1 articles in the media. Enveric Biosciences' average media sentiment score of 0.96 beat China Pharma's score of 0.00 indicating that Enveric Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment China Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enveric Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ENVB or SNTI?

Senti Biosciences has a consensus price target of $8.75, suggesting a potential upside of 770.65%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Senti Biosciences is more favorable than Enveric Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Senti Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Is ENVB or SNTI more profitable?

Enveric Biosciences' return on equity of -220.97% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Enveric Biosciences N/A -220.97% -177.47% Senti Biosciences N/A -532.05% -103.35%

Enveric Biosciences (ENVB) Competitors

$1.97 -0.01 (-0.45%)

As of 03:34 PM Eastern

Compare

ENVB vs. NNVC, SCYX, APLM, CPHI, and SNTI

Should you buy Enveric Biosciences stock or one of its competitors? MarketBeat compares Enveric Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Enveric Biosciences include NanoViricides (NNVC), SCYNEXIS (SCYX), Apollomics (APLM), China Pharma (CPHI), and Senti Biosciences (SNTI). These companies are all part of the "pharmaceutical products" industry.

How does Enveric Biosciences compare to NanoViricides?

NanoViricides (NYSE:NNVC) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

10.3% of NanoViricides shares are held by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are held by institutional investors. 3.6% of NanoViricides shares are held by company insiders. Comparatively, 2.4% of Enveric Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

NanoViricides has a beta of 1.66, suggesting that its stock price is 66% more volatile than the broader market. Comparatively, Enveric Biosciences has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market.

In the previous week, Enveric Biosciences had 1 more articles in the media than NanoViricides. MarketBeat recorded 1 mentions for Enveric Biosciences and 0 mentions for NanoViricides. Enveric Biosciences' average media sentiment score of 0.96 beat NanoViricides' score of 0.00 indicating that Enveric Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
NanoViricides	Neutral
Enveric Biosciences	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NanoViricides is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A
Enveric Biosciences	N/A	N/A	-$8.77M	-$23.54	N/A

NanoViricides' return on equity of -87.90% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NanoViricides	N/A	-87.90%	-78.69%
Enveric Biosciences	N/A	-220.97%	-177.47%

Summary

NanoViricides beats Enveric Biosciences on 8 of the 12 factors compared between the two stocks.

How does Enveric Biosciences compare to SCYNEXIS?

Enveric Biosciences (NASDAQ:ENVB) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

13.8% of Enveric Biosciences shares are held by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are held by institutional investors. 2.4% of Enveric Biosciences shares are held by insiders. Comparatively, 4.1% of SCYNEXIS shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Enveric Biosciences has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -57.16% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enveric Biosciences	N/A	-220.97%	-177.47%
SCYNEXIS	-41.79%	-57.16%	-39.48%

SCYNEXIS has higher revenue and earnings than Enveric Biosciences. SCYNEXIS is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enveric Biosciences	N/A	N/A	-$8.77M	-$23.54	N/A
SCYNEXIS	$20.60M	1.32	-$8.61M	-$3.84	N/A

In the previous week, Enveric Biosciences and Enveric Biosciences both had 1 articles in the media. Enveric Biosciences' average media sentiment score of 0.96 beat SCYNEXIS's score of 0.93 indicating that Enveric Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enveric Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SCYNEXIS	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SCYNEXIS has a consensus target price of $24.00, suggesting a potential upside of 390.80%. Given SCYNEXIS's stronger consensus rating and higher probable upside, analysts clearly believe SCYNEXIS is more favorable than Enveric Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Enveric Biosciences has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

Summary

SCYNEXIS beats Enveric Biosciences on 10 of the 14 factors compared between the two stocks.

How does Enveric Biosciences compare to Apollomics?

Apollomics (NASDAQ:APLM) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

19.1% of Apollomics shares are owned by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are owned by institutional investors. 2.4% of Enveric Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Apollomics' return on equity of 0.00% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Enveric Biosciences	N/A	-220.97%	-177.47%

In the previous week, Enveric Biosciences had 1 more articles in the media than Apollomics. MarketBeat recorded 1 mentions for Enveric Biosciences and 0 mentions for Apollomics. Apollomics' average media sentiment score of 1.87 beat Enveric Biosciences' score of 0.96 indicating that Apollomics is being referred to more favorably in the media.

Company	Overall Sentiment
Apollomics	Very Positive
Enveric Biosciences	Positive

Enveric Biosciences has lower revenue, but higher earnings than Apollomics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	3.61	-$10.94M	N/A	N/A
Enveric Biosciences	N/A	N/A	-$8.77M	-$23.54	N/A

Apollomics has a beta of 1.53, indicating that its share price is 53% more volatile than the broader market. Comparatively, Enveric Biosciences has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market.

Summary

Apollomics beats Enveric Biosciences on 6 of the 9 factors compared between the two stocks.

How does Enveric Biosciences compare to China Pharma?

China Pharma (NYSE:CPHI) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

In the previous week, China Pharma and China Pharma both had 1 articles in the media. Enveric Biosciences' average media sentiment score of 0.96 beat China Pharma's score of 0.00 indicating that Enveric Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
China Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enveric Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Enveric Biosciences has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
Enveric Biosciences	N/A	-220.97%	-177.47%

13.8% of Enveric Biosciences shares are held by institutional investors. 6.4% of China Pharma shares are held by insiders. Comparatively, 2.4% of Enveric Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

China Pharma has higher revenue and earnings than Enveric Biosciences. China Pharma is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.99M	9.18	-$3.08M	-$0.55	N/A
Enveric Biosciences	N/A	N/A	-$8.77M	-$23.54	N/A

China Pharma has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, Enveric Biosciences has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

China Pharma beats Enveric Biosciences on 7 of the 12 factors compared between the two stocks.

How does Enveric Biosciences compare to Senti Biosciences?

Enveric Biosciences (NASDAQ:ENVB) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

13.8% of Enveric Biosciences shares are owned by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are owned by institutional investors. 2.4% of Enveric Biosciences shares are owned by company insiders. Comparatively, 3.1% of Senti Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Senti Biosciences has a consensus price target of $8.75, suggesting a potential upside of 770.65%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Senti Biosciences is more favorable than Enveric Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Enveric Biosciences has higher earnings, but lower revenue than Senti Biosciences. Senti Biosciences is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enveric Biosciences	N/A	N/A	-$8.77M	-$23.54	N/A
Senti Biosciences	$20K	1,565.29	-$61.44M	-$1.92	N/A

In the previous week, Enveric Biosciences had 1 more articles in the media than Senti Biosciences. MarketBeat recorded 1 mentions for Enveric Biosciences and 0 mentions for Senti Biosciences. Senti Biosciences' average media sentiment score of 1.89 beat Enveric Biosciences' score of 0.96 indicating that Senti Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Enveric Biosciences	Positive
Senti Biosciences	Very Positive

Enveric Biosciences' return on equity of -220.97% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enveric Biosciences	N/A	-220.97%	-177.47%
Senti Biosciences	N/A	-532.05%	-103.35%

Enveric Biosciences has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market. Comparatively, Senti Biosciences has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market.

Summary

Senti Biosciences beats Enveric Biosciences on 11 of the 15 factors compared between the two stocks.

Get Enveric Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENVB vs. The Competition

Export

Metric	Enveric Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.39M	$3.34B	$6.43B	$12.49B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	-0.09	18.86	23.86	24.42
Price / Sales	N/A	320.30	521.12	117.04
Price / Cash	N/A	110.40	41.27	57.13
Price / Book	0.29	6.81	10.04	6.74
Net Income	-$8.77M	$24.09M	$3.56B	$337.03M
7 Day Performance	-13.36%	-2.39%	-0.81%	0.24%
1 Month Performance	N/A	N/A	N/A	-1.67%
1 Year Performance	-87.02%	48.97%	28.80%	34.36%

Enveric Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENVB Enveric Biosciences	1.1101 of 5 stars	$1.97 -0.5%	N/A	-87.0%	$7.34M	N/A	N/A	20
NNVC NanoViricides	0.1805 of 5 stars	$1.51 -7.9%	N/A	+2.7%	$32.69M	N/A	N/A	20	High Trading Volume
SCYX SCYNEXIS	2.1532 of 5 stars	$0.68 -6.9%	$3.00 +340.5%	-33.9%	$32.66M	$20.60M	N/A	60
APLM Apollomics	1.1933 of 5 stars	$14.09 -1.5%	N/A	+115.7%	$30.93M	$8.50M	N/A	45	Positive News
CPHI China Pharma	N/A	$0.76 +0.0%	N/A	-46.0%	$30.80M	$3.99M	N/A	250

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENVB) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enveric Biosciences (ENVB) Competitors

ENVB vs. NNVC, SCYX, APLM, CPHI, and SNTI

How does Enveric Biosciences compare to NanoViricides?

Summary

How does Enveric Biosciences compare to SCYNEXIS?

Summary

How does Enveric Biosciences compare to Apollomics?

Summary

How does Enveric Biosciences compare to China Pharma?

Summary

How does Enveric Biosciences compare to Senti Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENVB vs. The Competition

Enveric Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enveric Biosciences (ENVB) Competitors

ENVB vs. NNVC, SCYX, APLM, CPHI, and SNTI

How does Enveric Biosciences compare to NanoViricides?

Do insiders & institutionals hold more shares of NNVC or ENVB?

Which has more volatility & risk, NNVC or ENVB?

Does the media refer more to NNVC or ENVB?

Do analysts rate NNVC or ENVB?

Which has preferable valuation & earnings, NNVC or ENVB?

Is NNVC or ENVB more profitable?

Summary

How does Enveric Biosciences compare to SCYNEXIS?

Do insiders and institutionals hold more shares of ENVB or SCYX?

Is ENVB or SCYX more profitable?

Which has higher valuation and earnings, ENVB or SCYX?

Does the media refer more to ENVB or SCYX?

Do analysts prefer ENVB or SCYX?

Which has more risk and volatility, ENVB or SCYX?

Summary

How does Enveric Biosciences compare to Apollomics?

Do insiders & institutionals believe in APLM or ENVB?

Do analysts recommend APLM or ENVB?

Is APLM or ENVB more profitable?

Does the media favor APLM or ENVB?

Which has preferable earnings and valuation, APLM or ENVB?

Which has more volatility & risk, APLM or ENVB?

Summary

How does Enveric Biosciences compare to China Pharma?

Does the media favor CPHI or ENVB?

Is CPHI or ENVB more profitable?

Do institutionals & insiders have more ownership in CPHI or ENVB?

Which has better valuation and earnings, CPHI or ENVB?

Which has more volatility & risk, CPHI or ENVB?

Do analysts rate CPHI or ENVB?

Summary

How does Enveric Biosciences compare to Senti Biosciences?

Do insiders and institutionals hold more shares of ENVB or SNTI?

Do analysts recommend ENVB or SNTI?

Which has higher earnings and valuation, ENVB or SNTI?

Does the media refer more to ENVB or SNTI?

Is ENVB or SNTI more profitable?

Which has more risk & volatility, ENVB or SNTI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENVB vs. The Competition

Enveric Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools